摘要
中国国家食品药品监督管理局已批准4类核苷和核苷酸类药物(nucleoside and nucleotide analogs,NAs)用于慢性乙型肝炎患者(chronic hepatitis B,CHB)治疗。用这些药物可对CHB患者进行有效治疗,但常发生乙型肝炎病毒(HBV)对NAs的耐药,导致治疗失败和疾病进展。本文综述了HBV对NAs的耐药机制,以及专家对耐药管理和预防的共识。
Four nucleos（t）ide analogs （NAs） have been approved by the Food and Drug Administration, China for treatment of patients with chronic hepatitis B （CHB）. The patients can be successfully treated using NAs, but drugresistant hepatitis B virus （HBV） mutants frequently arise, leading to treatment failure and progression of the disease. This paper has reviewed the mechanisms of resistance to NAs, and consensus on the management and prevention of HBV resistance to NAs.
出处
《传染病信息》
2013年第1期1-9,共9页
Infectious Disease Information
关键词
肝炎
乙型
慢性
耐药
核苷和核苷酸类药物
管理
hepatitis B, chronic
drug resistance
nucleoside and nucleotide analogs
management
